Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

• Main Authors: Antonio Lacquaniti (Author), Patrizio Pasqualetti (Author), Teresa Casuscelli di Tocco (Author), Susanna Campo (Author), Stefania Rovito (Author), Maurizio Bucca (Author), Antonino Ragusa (Author), Paolo Monardo (Author)
• Formato: Libro
• Publicado: The Korean Society of Nephrology, 2020-09-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...